Bevacizumab safety in patients with central nervous system metastases

Clinical Cancer Research

Volumn 16, Issue 1, 2010, Pages 269-278

  Besse, Benjamin ^a   Lasserre, Susan F ^b   Compton, Peter ^c   Huang, Jane ^c   Augustus, Stella ^b   Rohr, Ulrich Peter ^b  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CISPLATIN; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; PLACEBO; STEROID;

ARTICLE; BRAIN HEMORRHAGE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; COLORECTAL CANCER; DISEASE SEVERITY; DRUG EXPOSURE; DRUG SAFETY; EXPLORATORY RESEARCH; HEMOPTYSIS; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG NON SMALL CELL CANCER; METASTASIS; MORTALITY; OPEN STUDY; PANCREAS CANCER; PANCREATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; CEREBRAL HEMORRHAGE; FEMALE; HUMANS; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK;

EID: 74949092481     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2439     Document Type: Article

References (43)

1. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-6.
2. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-5.
3. Rosen LS. VEGF-targeted therapy: therapeutic potential and recent advances. Oncologist 2005;10:382-91.
4. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370:2103-11.
5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
6. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-91.
7. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
8. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50.
9. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
10. Choi HJ, Cho BC, Sohn JH, et al. Brain metastases from hepatocellular carcinoma: prognostic factors and outcome: brain metastasis from HCC. J Neurooncol 2009;91:307-13.
11. Chang L, Chen YL, Kao MC. Intracranial metastasis of hepatocellular carcinoma: review of 45 cases. Surg Neurol 2004;62:172-7.
12. Murakami K, Nawano S, Moriyama N, et al. Intracranial metastases of hepatocellular carcinoma: CT and MRI. Neuroradiology 1996;38 Suppl 1:S31-5.
13. Seinfeld J, Wagner AS, Kleinschmidt-DeMasters BK. Brain metastases from hepatocellular carcinoma in US patients. J Neurooncol 2006;76:93-8.
14. Socinski MA, Langer CJ, Huang JE, et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 2009;27:5255-61.
15. Archer V, Reck M, Sandler AB, et al. Risk of symptomatic central nervous system (CNS) progression and secondary hemorrhage in patients with non-squamous non-small cell lung cancer (NSCLC) receiving bevacizumab (BV)-based first-line therapy. J Clin Oncol 2008;26:15s. abstr 8114.
16. Morgensztern D, Govindan R. Treatment of patients excluded from Eastern Cooperative Oncology Group 4599 and AVAiL studies: focus on brain metastasis and squamous histology. Clin Lung Cancer 2008;9 Suppl 2:S57-61.
17. Oh Y, Stewart DJ. Systemic therapy for lung cancer brain metastases: a rationale for clinical trials. Oncology (Williston Park) 2008;22:168-178; discussion 178, 183, 188 passim.
18. Bokstein F, Shpigel S, Blumenthal DT. Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 2008;112:2267-73.
19. Desjardins A, Reardon DA, Herndon JE II, et al. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clin Cancer Res 2008;14:7068-73.
20. Lai A, Filka E, McGibbon B, et al. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys 2008;71:1372-80.
21. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 2009;27:1227-34.
22. Van Cutsem E, Vervenne WL, Bennouna J, et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. J Clin Oncol 2009;27:2231-7.
23. Miles D, Chan A, Romieu G, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J Clin Oncol 2008;26:15s. abstr LBA1011.
24. Saltz LB, Clarke S, Díaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008;26:2013-9.
25. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-linemetastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23:3697-705.
26. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
27. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
28. Giantonio BJ, Catalano PJ, Meropol NJ, et al., for the Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007;25:1539-44.
29. Dansin E, Mezger J, Isla D, et al. Safety of bevacizumab-based therapy as first-line treatment of patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): MO19390 (SAiL). J Clin Oncol 2008;26:15s. abstr 8085.
30. Pierga J, Pritchard KI, Cortes-Funes H, et al. MO19391: An open-label safety study of bevacizumab plus taxane-based therapy as first-line treatment of patients with locally recurrent (LR) or metastatic breast cancer (MBC). J Clin Oncol 2008;26:15s. abstr 1140.
31. Polikoff J, Hainsworth JD, Fehrenbacher L, et al. Safety of bevacizumab (Bv) therapy in combination with chemotherapy in subjects with non-small cell lung cancer (NSCLC) treated on ATLAS. J Clin Oncol 2008;26:15s. abstr 8079.
32. Yoo H, Nam BH, Yang HS, Shin SH, Lee JS, Lee SH. Growth rates of metastatic brain tumors in nonsmall cell lung cancer. Cancer 2008;113:1043-7.
33. Byrne TN, Cascino TL, Posner JB. Brain metastasis from melanoma. J Neurooncol 1983;1:313-7.
34. Lieu AS, Hwang SL, Howng SL, Chai CY. Brain tumors with hemorrhage. J Formos Med Assoc 1999;98:365-7.
35. Maiuri F, D'Andrea F, Gallicchio B, Carandente M. Intracranial hemorrhages in metastatic brain tumors. J Neurosurg Sci 1985;29:37-41.
36. Mandybur TI. Intracranial hemorrhage caused by metastatic tumors. Neurology 1977;27:650-5.
37. Mathieu D, Kondziolka D, Cooper PB, et al. Gamma knife radiosurgery in the management of malignant melanoma brain metastases. Neurosurgery 2007;60:471-82.
38. Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol 2008;10:624-30.
39. Labidi S, Bachelot T, Ray Coquard IL, et al. Bevacizumab and paclitaxel for breast cancer patients with central nervous system metastases: a case series. Clin Breast Cancer 2009;9:118-21.
40. Bhaskara A, Eng C. Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. Clin Colorectal Cancer 2008;7:65-8.
41. Gonzalez-Cao M, Viteri S, Diaz-Lagares A, et al. Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma. Oncology 2008;74:12-6.
42. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27:4733-40.
43. Nutt SH, Patchell RA. Intracranial hemorrhage associated with primary and secondary tumors. Neurosurg Clin N Am 1992;3:591-9.